Lipidor Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Ola Holmlund

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	6yrs
CEO ownership	0.05%
Management average tenure	15.7yrs
Board average tenure	4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ola Holmlund's remuneration changed compared to Lipidor's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-SEK 14m
Mar 31 2024	n/a	n/a	-SEK 12m
Dec 31 2023	n/a	n/a	-SEK 11m
Sep 30 2023	n/a	n/a	-SEK 15m
Jun 30 2023	n/a	n/a	-SEK 25m
Mar 31 2023	n/a	n/a	-SEK 30m
Dec 31 2022	n/a	n/a	-SEK 41m
Sep 30 2022	n/a	n/a	-SEK 44m
Jun 30 2022	n/a	n/a	-SEK 28m
Mar 31 2022	n/a	n/a	-SEK 28m
Dec 31 2021	n/a	n/a	-SEK 21m
Sep 30 2021	n/a	n/a	-SEK 15m
Jun 30 2021	n/a	n/a	-SEK 23m
Mar 31 2021	n/a	n/a	-SEK 18m
Dec 31 2020	n/a	n/a	-SEK 16m
Sep 30 2020	n/a	n/a	-SEK 15m
Jun 30 2020	n/a	n/a	-SEK 14m
Mar 31 2020	n/a	n/a	-SEK 14m
Dec 31 2019	n/a	n/a	-SEK 14m
Sep 30 2019	n/a	n/a	-SEK 13m
Jun 30 2019	n/a	n/a	-SEK 10m
Mar 31 2019	n/a	n/a	-SEK 9m
Dec 31 2018	SEK 439k	SEK 300k	-SEK 8m

Compensation vs Market: Insufficient data to establish whether Ola's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Insufficient data to compare Ola's compensation with company performance.

CEO

Ola Holmlund (55 yo)

6yrs

Tenure

SEK 439,000

Compensation

Mr. Ola Holmlund serves as the Chief Executive Officer at Lipidor AB (publ) since September 1, 2018. He served as the Head of Sales at Kibion AB. He has experience in international sales and the launch of...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ola Holmlund	Chief Executive Officer	6yrs	SEK 439.00k	0.045% SEK 4.4k
Olle Holmertz	Founder & Business Controller	15.7yrs	SEK 540.00k	no data
Anders Carlsson	Co-Founder	15.7yrs	SEK 136.00k	no data
Bengt Herslöf	Co-founder & Senior Scientific Advisor	15.7yrs	no data	no data
Jan Holmbäck	Co-Founder & Chief Scientific Officer	15.7yrs	no data	0.11% SEK 10.2k
Gerhard Miksche	Co-Founder	15.7yrs	no data	no data
Charlotta Ekman	Chief Financial Officer	1.9yrs	no data	no data
Vibhu Rinwa	Chief Operating Officer	less than a year	no data	0.0044% SEK 424.1

15.7yrs

Average Tenure

55yo

Average Age

Experienced Management: L7R's management team is seasoned and experienced (15.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gunilla Lundmark	Independent Director	4.7yrs	no data	no data
Ola Flink	Independent Director	7.7yrs	SEK 31.00k	0.059% SEK 5.7k
Otto Skolling	Independent Director	4.3yrs	no data	no data
Fredrik Sjovall	Independent Chairman of the Board	6.7yrs	SEK 226.00k	0.0049% SEK 474.3
Denis Angioletti	Independent Director	4.3yrs	no data	no data

4.7yrs

Average Tenure

61yo

Average Age

Experienced Board: L7R's board of directors are considered experienced (4.7 years average tenure).

Lipidor Management

Management criteria checks 2/4

Key information

Recent management updates

Lipidor AB (publ), Annual General Meeting, Jun 05, 2024

Insufficient new directors

Lipidor AB (publ), Annual General Meeting, Jun 08, 2023

Lipidor AB (Publ) Appoints Charlotta Ekman as Chief Financial Officer, with Effect from October 1, 2022

Lipidor AB (Publ) Announces Nomination Committee

Recent updates

Lipidor AB (publ) Announces First Patient Enrolled in Phase III Study of AKP02G2 for Topical Treatment of Psoriasis

New major risk - Shareholder dilution

Lipidor AB (publ) to Report Fiscal Year 2024 Results on Feb 28, 2025

Lipidor AB (publ) Announces That Clinical Trial Material for Psoriasis Candidate AKP02G2 Has Been Releases According to Plan

First quarter 2024 earnings released: EPS: kr0.011 (vs kr0.014 in 1Q 2023)

Lipidor AB (publ) to Report Fiscal Year 2023 Final Results on May 15, 2024

Lipidor AB (publ) Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2

Full year 2023 earnings released: kr0.40 loss per share (vs kr1.43 loss in FY 2022)

Lipidor Applies to the Indian Medical Products Agency to Start A Phase III study of AKP02G2

Lipidor AB (publ), Annual General Meeting, Jun 05, 2024

Lipidor AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Lipidor AB (publ) Files New Patent Application with the European Patent Office

Second quarter 2023 earnings released: kr0.13 loss per share (vs kr0.30 loss in 2Q 2022)

Insufficient new directors

Lipidor AB (Publ) Confirms Clinical Plan for New Version of Akp02

Full year 2022 earnings released: kr1.43 loss per share (vs kr0.75 loss in FY 2021)

Lipidor AB (publ), Annual General Meeting, Jun 08, 2023

Lipidor AB (publ) to Report Nine Months, 2023 Results on Nov 22, 2023

Lipidor AB (Publ) Provides Update Following Outcome of Phase Iii Study of Psoriasis Candidate Akp02

Lipidor AB (publ) Announces Results from the Its Clinical Phase III Study of AKP02 for Psoriasis

Lipidor Updates on Phase III Clinical Study of Psoriasis Candidate AKP02

Second quarter 2022 earnings released: kr0.30 loss per share (vs kr0.26 loss in 2Q 2021)

Lipidor AB (Publ) Appoints Charlotta Ekman as Chief Financial Officer, with Effect from October 1, 2022

Lipidor AB (Publ) Announces All Patients in Lipidor's Phase III Study with Psoriasis Candidate Akp02 Have Completed Treatment

Lipidor AB (publ) Announces Last Patient Has Been Enrolled in the Ongoing Phase III Study of AKP02 Against Mild to Moderate Psoriasis

Lipidor Ordinary Shares to Be Deleted from OTC Equity

Lipidor Updates on Phase III Study of AKP02 in Treatment of Psoriasis

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis

Lipidor AB (Publ) Expands Clinical Program, Announces Investment in New Drug Development Project Against Acne Vulgaris

No longer forecast to breakeven

Lipidor AB (publ) Announces Approval to Start Phase III Clinical Study of Drug Candidate Akp02 for Treatment of Psoriasis

New 90-day low: €1.04

New 90-day low: €1.17

Cannassure Therapeutics Ltd., Enters into Exclusive Licensing Agreement Regarding Topical Medical Cannabis Products Based on Lipidor's Akvano Technology

Lipidor AB and Cannassure Therapeutics Ltd Enter Exclusive Licensing Agreement Regarding Topical Medical Cannabis Products Based on Lipidor's Akvano® Technology

Lipidor AB (publ) to Report Q3, 2021 Results on Nov 17, 2021

Lipidor Signs Cooperation Agreement with Aurena Laboratories AB to Offer Licensees the Opportunity for GMP Production

Lipidor AB (Publ) Announces Nomination Committee

Lipidor AB (publ) to Report Q1, 2021 Results on May 06, 2021

Lipidor Announces Positive Outcome of Feasibility Study for Development of Topical Medical Cannabis Products Based on the Company's Akvano® Technology

First half earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age